No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 30 of the 40 quarters in the window, leaving 10 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 103.8x · 10Y median 21.1x · 67th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:27:31.323Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Lisata Therapeutics, Inc. (LSTA) stock was $1.14 as of Oct 6, 2026, 12:24 PM EDT, down 9.52% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -49.8% · 3-year avg -15.6%/yr · 5-year avg -40.8%/yr
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies.
Biotechnology · Basking Ridge, NJ
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-1.13
Revenue Est.
$659000.00
Last Quarter Results
EPS
$-0.49
vs Estimate
$-0.54
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LSTA | $10.38M | $1.14 | -9.52% | -49.83% | -40.75% | -32.84% | N/A |
| 2MSLE | $10.44M | $8.11 | +0.72% | N/A | N/A | N/A | vs LSTA |
| 3PLRZ | $10.47M | $9.35 | +0.94% | +41.36% | N/A | N/A | vs LSTA |
| 4GDTC | $10.64M | $0.90 | -11.01% | -49.59% | N/A | N/A | vs LSTA |
| 5CABR | $10.68M | $1.18 | +3.98% | -69.29% | N/A | N/A | vs LSTA |
| 6MTVA | $10.08M | $1.53 | -0.65% | -86.28% | N/A | N/A | vs LSTA |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Average Price Target
N/A
Low
N/A
Current
$1.14
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.13 | $-1.13 | $-1.13 | 1 |
| Quarter ending Dec 2026 | $-2.17 | $-2.17 | $-2.17 | 1 |
| Quarter ending Mar 2027 | $-1.95 | $-1.95 | $-1.95 | 1 |
| Quarter ending Jun 2027 | $-1.85 | $-1.85 | $-1.85 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.09 | $-1.09 | $-1.09 | 1 |
| FY 2027 | $-1.16 | $-1.16 | $-1.16 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $659000.00 | $659000.00 | $659000.00 | 1 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $134725.00 | $134725.00 | $134725.00 | 1 |
| FY 2027 | $5.00M | $5.00M | $5.00M | 1 |
